Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Dottikon Es Holding AG    DESN   CH0582581713

DOTTIKON ES HOLDING AG

(DESN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Dottikon ES : Shareholders Approve all Proposals of the Board of Directors

07/05/2019 | 02:28pm EST

MEDIA RELEASE

Dottikon, July 5, 2019

DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 5, 2019 - The shareholders approved all proposals of the Board of Directors at the 14th Annual General Meeting of DOTTIKON ES HOLDING AG in Dottikon. The 131 present shareholders represented 1'165'114 voting rights and therefore 95.4% of the total of 1'221'537 registered shares with voting rights.

The Annual Report, the financial statements 2018/19, and the Group financial statements 2018/19 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. The Compensation Report 2018/19 was presented to and taken notice of by the Annual General Meeting. Discharge for the business year 2018/19 was granted to the responsible members of the Board of Directors and Senior Management. Further, the proposal of the Board of Directors to carry forward the entire retained earnings to new account and to pay no dividend was accepted. The previous Chairman of the Board of Directors Dr. Markus Blocher was confirmed for another one-year term. Dr. Thomas Früh was reelected for a one-year term as Deputy Chairman and Dr. Alfred Scheidegger as member of the Board. All three Board members were reelected for a term of one year as members of the Compensation Committee. Dr. Markus Blocher was elected as its Chairman and Dr. Thomas Früh as Deputy Chairman. The proposed maximum amounts of prospective remunerations for the Board of Directors and Senior Management, respectively, were approved. KPMG AG, Zug, was reelected as external auditor for another one-year term. Dr. iur. Michael Wicki, attorney-at-law and notary public, was reelected as independent proxy for the 15th Annual General Meeting.

DOTTIKON ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and is positioning itself as strategic development and manufacturing part ner. Its safety culture created over 105 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons.

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent communication with customers.

Dottikon ES Holding AG

P.O. Box, 5605 Dottikon, Switzerland, Tel +41 56 616 81 11, Fax +41 56 616 89 45, investor-relations@dottikon.com, www.dottikon.com

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange. Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.

CEO

Dottikon ES Holding AG

Tel +41 56 616 82 01

Fax +41 56 616 89 45 investor-relations@dottikon.com

Dottikon ES Holding AG

P.O. Box, 5605 Dottikon, Switzerland, Tel +41 56 616 81 11, Fax +41 56 616 89 45, investor-relations@dottikon.com, www.dottikon.com

Disclaimer

Dottikon ES Holding AG published this content on 05 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2019 18:27:10 UTC


© Publicnow 2019
All news about DOTTIKON ES HOLDING AG
2020DOTTIKON ES HOLDING AG : SPLIT: 10 of 1
FA
2020Dottikon ES CEO Plans to Retain Control With 72% Stake; Shares Jump 9%
MT
2020Dottikon ES Soars 16% as Shareholders OK Stock Split, Capital Raise
MT
2020DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
2020Dottikon ES to Invest $304 Million in New Chemical Multipurpose Production Pl..
MT
2020Dottikon ES Stock Drops as Fiscal H1 Net Income Soars 37%
MT
2020HALF-YEAR REPORT 2020/21 : Growth, Higher Profitability and Construction of New ..
PU
2020DOTTIKON ES HOLDING AG : half-yearly earnings release
2020DOTTIKON ES : Shareholders Approve all Proposals of the Board of Directors
PU
2020DOTTIKON ES : Condensed Annual Report 2019/20
PU
More news
Financials
Sales 2020 175 M 197 M 197 M
Net income 2020 33,2 M 37,3 M 37,3 M
Net cash 2020 42,8 M 48,2 M 48,2 M
P/E ratio 2020 24,3x
Yield 2020 -
Capitalization 2 464 M 2 776 M 2 773 M
EV / Sales 2019 3,47x
EV / Sales 2020 4,36x
Nbr of Employees 630
Free-Float 21,4%
Chart DOTTIKON ES HOLDING AG
Duration : Period :
Dottikon Es Holding AG Technical Analysis Chart | DESN | CH0582581713 | MarketScreener
Technical analysis trends DOTTIKON ES HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Markus Blocher Chairman, Chief Executive Officer & MD
Marlene Born Chief Financial Officer
Urs Bršndli Head-Processes & Technologies
Alfred Scheidegger Non-Executive Director
Stephan Kirschbaum Head-Business Development
Sector and Competitors
1st jan.Capitalization (M$)
DOTTIKON ES HOLDING AG17.26%2 776
MERCK KGAA6.66%79 055
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD9.60%27 322
KYOWA KIRIN CO., LTD.-0.89%14 451
BETTA PHARMACEUTICALS CO., LTD.12.41%7 513
YUHAN CORPORATION3.60%4 412